Modeling complex treatment strategies: Construction and validation of a discrete event simulation model for glaucoma

Value in Health

Volumn 13, Issue 4, 2010, Pages 358-367

  Van Gestel, Aukje ^a   Severens, Johan L ^a,b   Webers, Carroll A B ^a   Beckers, Henny J M ^a   Jansonius, Nomdo M ^c   Schouten, Jan S A G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Discrete event simulation; disease progression model; modeling; ocular hypertension; primary open angle glaucoma; validation

Indexed keywords

ARTICLE; CONSTRUCT VALIDITY; COST BENEFIT ANALYSIS; DISEASE COURSE; INTRAOCULAR HYPERTENSION; MEDICAL DECISION MAKING; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PRIMARY GLAUCOMA; PRIORITY JOURNAL; SIMULATION; VALIDATION STUDY; BIOLOGICAL MODEL; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; ECONOMICS; GLAUCOMA; HUMAN; MIDDLE AGED; NETHERLANDS; PATHOPHYSIOLOGY; QUALITY ADJUSTED LIFE YEAR; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; HUMANS; LIKELIHOOD FUNCTIONS; MIDDLE AGED; MODELS, BIOLOGICAL; NETHERLANDS; OCULAR HYPERTENSION; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 77954305660     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00678.x     Document Type: Article

References (37)

1. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006 24 : 1043 1053.
2. Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Man Sci 1998 1 : 133 140.
3. Karnon J. Alternative decision modelling techniques for the evaluation of health care technologies: markov processes versus discrete event simulation. Health Econ 2003 12 : 837 848.
4. Heeg BM, Damen J, Buskens E, et al. Modelling approaches: the case of schizophrenia. Pharmacoeconomics 2008 26 : 633 648.
5. Eddy DM. Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. Pharmacoeconomics 2006 24 : 837 844.
6. Maier P, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005 331 : 134.
7. Peeters A, Webers C, Prins M, et al. Quantifying the effect of intra-ocular pressure reduction on the occurrence of glaucoma. Acta Ophthalmol in press.
8. American Academy of Ophthalmology Glaucoma Panel. Primary Open-Angle Glaucoma. Preferred Practice Patterns.
9. European Glaucoma Society. Terminology and Guidelines for Glaucoma (3rd ed.).
10. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation (1st ed.).
11. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006 24 : 355 371.
12. Weinstein M, O'Brien B, Hornberger J, et al. Principles of good practice of decision analytic modeling in health care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 2003 6 : 9 17.
13. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 2002 11 : 531 539.
14. Realini T, Fechtner R. 56,000 ways to treat glaucoma. Ophthalmology 2002 109 : 1955 1956.
15. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004 363 : 1711 1720.
16. Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics 2008 26 : 131 148.
17. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004 9 : 110 118.
18. Cooper K, Brailsford S, Davies R. Choice of modelling technique for evaluating health care interventions. J Oper Res Soc 2007 58 : 168 176.
19. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006 15 : 1295 1310.
20. Law A, Kelton W. Simulation Modeling and Analysis (3rd ed.).
21. Heijl A, Patella V. Essential Perimetry; the Field Analyzer Primer (3rd ed.).
22. Gordon MO, Torri V, Miglior S, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007 114 : 10 19.
23. Statistics Netherlands (CBS). Mortality rates by age and gender. Available from: http://statline.cbs.nl/StatWeb/ [Accessed July 12, 2005
24. Heijl A, Leske C, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression; results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002 120 : 1268 1279.
25. Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.).
26. Rodenburg-Van Dieten H. Guidelines for Pharmacoeconomic Research (Version 2006).
27. Mangione C, Lee P, Gutierrez P, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001 119 : 1050 1058.
28. Van Gestel A, Webers C, Beckers H, et al. How does visual field loss in glaucoma affect generic and disease-specific health-related quality-of-life? World Glaucoma Congress, July 8-11, 2009.
29. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000 17 : 501 513.
30. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 2000 17 : 461 477.
31. Kass M, Heuer D, Higginbotham E, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocularhypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 120 : 701 713.
32. Chen P. Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003 110 : 726 733.
33. Wilson M, Kosoko O, Cowan C, et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol 2002 134 : 399 405.
34. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuations. Ophthalmology 2004 111 : 2109 2116.
35. Heeg G, Blanksma L, Hardus PLLJ, Jansonius N. The Groningen longitudinal glaucoma study. I. Baseline sensitivity and specificity of the frequency doubling perimeter and the GDx nerve fibre analyser. Acta Ophthalmol Scand 2005 83 : 46 52.
36. McKean Cowdin R, Varma R, Wu J, et al. Severity of visual field loss and health-related quality of life. Am J Ophthalmol 2007 143 : 1013 1023.
37. Rein D, Wittenborn J, Lee P, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 2009 116 : 823 832.